RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

This study is testing a new medication called daraxonrasib to see if it helps prevent pancreatic cancer from coming back after surgery. It compares this new targeted therapy to the usual standard of care, where patients are simply monitored by their doctors after their initial treatment.

You may be eligible if you are 18 or older and have had surgery to remove a common type of pancreatic cancer. You must have already completed your chemotherapy and have no current signs of the cancer returning.

Participants will be split into two groups: one receiving the new study drug and the other receiving standard observation. You will need to attend regular clinic visits and health check-ups so the research team can carefully monitor your progress and safety.

The study is currently recruiting patients at medical centers in Los Angeles and Palo Alto, California. Please talk to your oncology team to see if one of these locations is a good fit for you.